We are pleased to publish the Autumn 2019 issue of EUnetHTA Magazine. Intended for improved accessibility on whichever device you use, this issue includes various contributions from the EUnetHTA member network, while updating information on EUnetHTA products and the state
PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active
We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer", together with the input from external experts and manufacturers, are now available for access. Irreversible electroporation (IRE) is a nonthermal ablative method based on
We are pleased to roll out the next issue of EUnetHTA Magazine. As we are now experimenting with a web-based format, we hope to provide a more interactive experience for readers, whether that's on desktop, tablet, or mobile device. In this
EUnetHTA is pleased to announced that the document on "Patient Input in Relative Effectiveness Assessments" is now available. The document describes the process regarding direct patient input in REAs within JA3. The document is primarily intended for those who design and
PTJA04 – “Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy” is now available
This is the assessment of the relative effectiveness of ‘Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed
OTCA14 ”Robot-assisted surgery in thoracic and visceral indications”.” Final Assessment Now Available
We are pleased to announce publication of the collaborative assessment OTCA14 “Robot-assisted surgery for thoracic and visceral surgery”. This is the assessment of the relative effectiveness and safety of robot-assisted surgery for 13 different procedures within the thoracic and visceral surgery
We are pleased to announce that the collaborative rapid assessment, OTCA11, on "Custom-made or customisable 3D printed implants and cutting guides versus non-3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery"
EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.
Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.